Parathyroid hormone - Shire

Drug Profile

Parathyroid hormone - Shire

Alternative Names: 423562; ALX 111; Natpar; Natpara; NPSP-795; NPSP558; Parathyroid hormone (1-84) - Shire; PREOS; Preotact; PTH (1-84); PTH 1-84; Recombinant human parathyroid hormone-1-84; rhPTH (1-84); rhPTH-1-84; SB-423562; SHP-635

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NPS Pharmaceuticals
  • Developer National Institutes of Health (USA); NPS Pharmaceuticals; Shire; Takeda Pharmaceuticals International GmbH
  • Class Calcium regulators; Osteoporosis therapies; Peptide hormones
  • Mechanism of Action Calcium-sensing receptor antagonists; Osteogenesis stimulants; Parathyroid hormone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypoparathyroidism
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hypoparathyroidism; Postmenopausal osteoporosis
  • Phase II Hypocalcaemia
  • Discontinued Osteoporosis

Most Recent Events

  • 13 Dec 2017 Shire plans a phase III trial in Hypoparathyroidism (NCT03364738) (EudraCT2017-003067-36) (Trial profile 700291143)
  • 26 Jun 2017 Shire completes a phase I trial for Hypoparathyroidism (In volunteers) in USA (SC) (NCT03150108)
  • 16 May 2017 Shire initiates enrolment in a phase I trial for Hypoparathyroidism (In volunteers) in USA (SC) (NCT03150108)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top